Last updated 2026-07-25
TL;DR
Bremelanotide (PT-141, brand name Vyleesi) is not currently on the WADA Prohibited List, so it is not a banned substance in tested sports as of this writing. That said, it acts on the same melanocortin receptor family involved in metabolic and pigmentation pathways, so athletes should verify current status with their sport's anti-doping body before using it, not assume anything stays static.
Is PT-141 (bremelanotide) a banned substance for athletes?
As of this writing, bremelanotide is not named on the World Anti-Doping Agency Prohibited List. It is not a stimulant, not an anabolic agent, and not a diuretic or masking agent, the categories that dominate that list. It is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women [1], which puts it in a completely different clinical lane than performance-enhancing drugs. But "not currently listed" is not the same as "permanently cleared." Prohibited lists get updated every year, and drugs that touch metabolic or hormonal pathways sometimes draw scrutiny later even if they started out unrelated to athletic performance. Bremelanotide's target, the melanocortin 4 receptor, sits inside a system that also regulates body weight and energy balance [2], which is exactly the kind of overlap that anti-doping bodies watch. If you compete under a testing federation (NCAA, Olympic sports, a state athletic commission), check the current list yourself rather than trusting an article, including this one, to stay perfectly current. The honest answer: no evidence right now that it's prohibited, but this is a check-every-season situation, not a check-once situation.
Why does PT-141 work in the brain instead of the blood vessels?
This is the single most important thing to understand about bremelanotide, and it's also the reason it doesn't behave anything like a typical performance drug. Sildenafil (Viagra) and similar drugs work on vascular smooth muscle, increasing blood flow to genital tissue. Bremelanotide does none of that directly. It is a melanocortin receptor agonist, meaning it activates MC3R and MC4R receptors in the central nervous system, particularly in hypothalamic circuits tied to sexual motivation [3] . A 2022 review in CNS Spectrums lays out the neurobiology: bremelanotide's action on central melanocortin pathways is thought to drive the pro-sexual effect seen in premenopausal women with acquired, generalized hypoactive sexual desire disorder . It doesn't act like a vasodilator sitting downstream in the pelvis. It acts upstream, in the brain circuits that generate desire in the first place. This distinction matters for anyone thinking about doping angles. It has no mechanism for building muscle, increasing oxygen delivery to working tissue, or blunting fatigue perception the way stimulants or erythropoiesis-stimulating agents do. Its job is arousal signaling, not performance physiology. For dosing specifics, see PT-141 dosage.
Does PT-141 show up on a standard drug test?
No. Bremelanotide is a cyclic peptide, not a small molecule that shows up on routine urine drug screens for opioids, amphetamines, benzodiazepines, or THC. Standard workplace or clinical toxicology panels are not built to detect it, and it isn't a controlled substance under the Controlled Substances Act schedules. Sports anti-doping labs are a different animal. WADA-accredited labs run targeted mass spectrometry panels built specifically around the current Prohibited List, and they can and do add detection methods for peptides when a substance gets listed. So the fact that a standard drug test won't catch it tells you nothing about whether a sport-specific anti-doping panel would, if the substance were ever added to that list. Right now there's no indication it's a target, because it isn't prohibited. That could change with a future list update.
What is the clinical evidence behind bremelanotide, and does any of it involve athletic performance?
None of it does, and that's worth saying plainly. Every phase of bremelanotide's development targeted sexual desire disorder, not athletic performance. The two key phase 3 trials, known as RECONNECT, enrolled premenopausal women with acquired, generalized hypoactive sexual desire disorder and tested self-administered subcutaneous bremelanotide against placebo [4]. A prespecified subgroup analysis of that same RECONNECT program looked at how effects varied by age, menopausal proximity, and baseline desire severity [5]. A phase 2b dose-ranging study looked at responder rates across different doses to help settle on the 1.75 mg dose that became the approved regimen . None of these studies measured strength, endurance, reaction time, or recovery. The endpoints were entirely about sexual desire and related distress, scored on validated instruments. Separately, researchers have looked at bremelanotide's effect on body weight in obese women in phase 1 trials, since melanocortin receptor activation touches energy metabolism . That's a metabolic research thread, not a performance one, but it is the closest the literature comes to touching anything an athlete might care about, and it's still far from anything resembling ergogenic benefit.
Could PT-141 affect body composition or weight in a way relevant to athletes?
This is where the melanocortin system gets interesting scientifically, and where an athlete might reasonably ask questions, even though the honest answer is "probably not in a way that matters for performance." MC4R, the same receptor bremelanotide activates for sexual desire, is heavily involved in energy homeostasis and appetite regulation [2]. A 2022 study in Diabetes, Obesity & Metabolism looked specifically at body weight effects from bremelanotide in two phase 1 randomized controlled trials in obese women . That's a narrow, specific finding in a specific population, not a green light to think of bremelanotide as a weight-management or body-composition tool. Nobody has run trials looking at whether bremelanotide changes lean mass, fat oxidation during exercise, or recovery markers in athletes. The receptor overlap with metabolic pathways is real and it's part of why researchers are exploring melanocortin agonists for metabolic disease more broadly [2], but extrapolating from a phase 1 weight study in obese women to "this helps performance" is not something the data supports.
What side effects should an athlete weigh before using PT-141?
Nausea is the big one. It shows up in roughly 40% of women in the phase 3 trials at the approved 1.75 mg dose, according to the pooled safety analysis across the clinical development program [6]. Flushing is the second most common, and both are dose-related, meaning they get worse at higher doses and tend to fade with repeated use for many people. A pharmacotherapy review in Current Psychiatry Reports and a Medical Letter evaluation both flag the same top-line safety picture: nausea, flushing, headache, and injection site reactions dominate the adverse event list, with transient increases in blood pressure also reported [7] . That blood pressure bump matters specifically for anyone with existing hypertension or a cardiovascular condition, a concern detailed in a 2022 review on managing hypertension alongside female sexual dysfunction treatment . For an athlete, transient blood pressure elevation right after dosing is not something to dismiss, especially around training or competition timing. Full contraindication details are worth reading before considering use, see PT-141 contraindications and PT-141 and blood work.
How does PT-141 compare to other drugs athletes worry about testing positive for?
| Bremelanotide (PT-141) | Not currently listed | Central melanocortin receptor agonist | Not a targeted analyte on standard panels | |
|---|---|---|---|---|
| Anabolic steroids | Prohibited at all times | Androgen receptor activation | Weeks to months, lab-specific | |
| EPO / ESAs | Prohibited at all times | Increases red blood cell production | Days to weeks depending on formulation | |
| Stimulants (in-competition) | Prohibited in-competition | CNS stimulation, catecholamine release | Hours to days | |
| Sildenafil-class PDE5 inhibitors | Not prohibited | Vascular smooth muscle relaxation | Not tested for | The table makes the point visually: bremelanotide sits closer to PDE5 inhibitors than to steroids or EPO in terms of doping relevance, meaning essentially none, right now. But PDE5 inhibitors work on blood vessels. Bremelanotide works on brain receptors tied to appetite and energy signaling too, which is a different risk conversation even if it's not a doping conversation. |
Here's a quick comparison to put bremelanotide's regulatory position in context against drug classes athletes more commonly ask about. | Substance | WADA status | Mechanism | Typical detection window concern |
Why did some clinicians question how strong bremelanotide's effect really is?
Worth knowing regardless of the sports angle, because it shapes whether bremelanotide is worth using at all. A 2021 paper in Drug and Therapeutics Bulletin argued that regulatory approval of bremelanotide (and flibanserin before it) rested on comparisons to a precedent that didn't hold up well, calling it "the fallacy of regulatory precedent" . A separate re-analysis of the phase 3 trials published in the Journal of Sex Research pushed back on how "hypoactive sexual desire disorder" outcomes were measured and interpreted . A 2024 paper in the same journal, titled bluntly "Small Effects, Questionable Outcomes," argued the magnitude of benefit in the key trials was modest relative to the side effect burden . This isn't a fringe objection. It reflects a real, ongoing debate in the sexual medicine literature about how meaningful the RECONNECT trial results are in absolute terms, even though the FDA approval stands [4] [1]. None of this is a doping concern. It's a "does this actually work well enough to justify the nausea" concern, and it's worth reading regardless of why someone is considering the drug.
Does PT-141 interact with cardiovascular health in ways that matter for training?
Transient blood pressure increases after dosing are documented in the clinical safety data [6] , and a focused 2022 review addressed managing hypertension specifically in the context of female sexual dysfunction treatment . For most healthy adults these increases are modest and short-lived. For someone with uncontrolled hypertension or known cardiovascular disease, it's a different calculation, and it's one that belongs in a conversation with a prescriber, not a forum thread. Training load itself raises blood pressure transiently too, so stacking two blood-pressure-elevating events close together (a workout and a recent dose) is something to think through with a clinician rather than guess about. This is a case where getting baseline labs and a cardiovascular check before starting makes practical sense, more than box-checking. See PT-141 and blood work for what a reasonable workup looks like.
How is PT-141 actually dosed, and does timing matter for someone training or competing?
The FDA-approved regimen is a 1.75 mg subcutaneous injection, self-administered at least 45 minutes before anticipated sexual activity, with a maximum of one dose in 24 hours and no more than 8 doses per month [1] . It is not a daily medication and it is not built around a training or competition schedule at all, it's built around anticipated sexual activity timing. Because nausea and transient blood pressure changes cluster in the hours right after dosing [6], anyone using it around a training day would reasonably want distance between dosing and hard physical exertion, similar logic to not training immediately after a big meal or a new medication. Full dosing detail, including how the phase 2b dose-ranging data landed on 1.75 mg as the sweet spot between efficacy and tolerability , is covered in PT-141 dosage.
What about compounded or research-grade PT-141 versus the FDA-approved version?
This distinction matters more for athletes than almost anyone else, because unregulated sourcing is where actual doping risk hides. The FDA-approved product is Vyleesi, manufactured to pharmaceutical standards and reviewed through the normal drug approval pathway [1]. Compounded versions exist under different regulatory rules entirely: 21 U.S.C. 353a governs pharmacy compounding [source], and bulk substances used in 503A compounding are governed by a specific FDA bulks list under 21 CFR 216.23 [source]. Research chemical sellers marketing "PT-141" outside any pharmacy relationship are not operating under either of those frameworks, and purity, dose accuracy, and even the actual identity of the vial's contents are not verified by anyone. For an athlete, an unverified product is a bigger doping and safety risk than the approved drug itself could ever be, because you have no idea what else might be in it. If you're going to use bremelanotide, doing it through a provider-reviewed pathway with a real prescription is the only way to know what you're actually injecting. Storage matters too, since peptide degradation changes both potency and safety, covered in PT-141 storage and shelf life.
Should an athlete tell their team physician or anti-doping officer before using PT-141?
Yes, and this isn't complicated. Any competing athlete under a testing authority should disclose all medications and supplements to their team physician, because that physician is the one who tracks Prohibited List updates in real time and can flag a problem before it becomes a violation. Anti-doping rule violations sometimes happen not because someone used a banned substance knowingly, but because a substance moved onto a list and nobody was tracking it. Given that bremelanotide sits inside the melanocortin system, a pathway with real metabolic relevance under active research for obesity and related conditions [2], it is exactly the kind of drug that could see future regulatory attention even though it has none today. A five-minute conversation with a team physician costs nothing and closes that risk entirely.
Frequently asked questions
Is PT-141 banned by WADA?
No, bremelanotide is not currently on the WADA Prohibited List. It's FDA-approved as Vyleesi for hypoactive sexual desire disorder [4], not a performance-enhancing category drug. Still, check the current list yourself each season since it updates annually and melanocortin pathway drugs draw ongoing research attention.
Will PT-141 show up on a standard workplace drug test?
No. It's a peptide, not one of the small molecules (opioids, amphetamines, THC, benzodiazepines) that standard urine panels screen for. It is not a controlled substance. Sport-specific anti-doping panels could theoretically add detection if it were ever listed, but there's no indication that's happening.
Does PT-141 build muscle or improve athletic performance?
No. It's a central melanocortin receptor agonist that acts on brain pathways tied to sexual desire [7][19], not on muscle tissue, oxygen delivery, or fatigue perception. Its only FDA-approved use is hypoactive sexual desire disorder in premenopausal women [4]. There is no performance-enhancement mechanism or evidence behind it.
Why does PT-141 work differently from Viagra?
Sildenafil acts on vascular smooth muscle to increase blood flow. Bremelanotide acts centrally, activating MC3R and MC4R receptors in brain circuits tied to sexual motivation [7][19]. That's why it's dosed as an as-needed injection rather than a pill, and why its side effect profile (nausea, flushing) looks so different from PDE5 inhibitors.
What are the most common side effects of PT-141?
Nausea affects roughly 40% of users at the approved 1.75 mg dose, and flushing is the second most common effect [5]. Headache, injection site reactions, and transient blood pressure increases are also documented [10][18]. Side effects are dose-related and often lessen with repeated use for many people.
Can PT-141 raise blood pressure during exercise?
Bremelanotide causes transient blood pressure increases after dosing in clinical trials [5][23]. Combined with the natural blood pressure rise from exercise, this is worth discussing with a physician, especially for anyone with existing hypertension or cardiovascular disease, before timing a dose near a training session.
Is bremelanotide the same thing as PT-141?
Yes. PT-141 is the research-chemical name; bremelanotide is the drug's official name, and Vyleesi is the FDA-approved brand name for the 1.75 mg subcutaneous injection [4]. All three refer to the same molecule, though only the FDA-approved product has verified manufacturing and purity standards.
Does PT-141 affect body weight or metabolism?
It can, in a narrow context. A 2022 study looked specifically at bremelanotide's effect on body weight in obese women across two phase 1 trials [25], reflecting MC4R's known role in energy regulation [6]. That's not evidence it helps athletic performance or body composition in trained individuals; no such trials exist.
Do I need to tell my team doctor I'm using PT-141?
Yes. Even though it's not currently prohibited, disclosing all medications to a team physician or anti-doping officer is standard practice for any competing athlete. Prohibited lists change annually, and a physician tracking those updates can flag a future issue before it becomes a violation.
Is research-grade or compounded PT-141 safe for athletes to use?
It carries more risk than the FDA-approved product. Compounded versions fall under different rules (21 U.S.C. 353a, 21 CFR 216.23), and unregulated research chemical sellers verify nothing about purity or dose. For an athlete, an unverified vial is a bigger practical risk than the drug's doping status.
How is PT-141 dosed and does that matter for athletes?
The approved dose is 1.75 mg subcutaneous, taken at least 45 minutes before anticipated sexual activity, max once daily and 8 times monthly [4][18]. It's not scheduled around training, but nausea and blood pressure effects cluster in the hours after dosing, so spacing it away from hard training makes practical sense.
Is the evidence for PT-141's effectiveness strong?
It's modest and debated. The RECONNECT phase 3 trials showed statistically significant improvement over placebo [11], but a 2024 Journal of Sex Research paper titled "Small Effects, Questionable Outcomes" argued the clinical benefit was small relative to side effects [22], and a 2021 re-analysis raised similar concerns [24].
Sources
- PubMed, Obstetrics and Gynecology 2019 (PMID 31599840): RECONNECT phase 3 trials tested subcutaneous bremelanotide against placebo in premenopausal women with acquired, generalized HSDD
- PubMed, Drugs 2019, Bremelanotide: First Approval (PMID 31429064): Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, dosed 1.75 mg subcutaneous
- PubMed, Journal of Women's Health 2022, Safety Profile of Bremelanotide (PMID 35147466): Nausea occurs in roughly 40% of users at the approved dose, with flushing as the second most common adverse effect, and transient blood pressure increases documented
- PubMed, Nature Reviews Endocrinology 2023 (PMID 37365323): MC4R and the central melanocortin system are targets of active research for metabolic disorders including energy homeostasis
- PubMed, Neurology International 2022 (PMID 35076581): Bremelanotide's pro-sexual effect is driven by central melanocortin receptor activation rather than vascular mechanisms
- PubMed, Current Psychiatry Reports 2022 (PMID 35102537): Pharmacotherapy review confirms nausea, flushing, and headache as dominant adverse events for bremelanotide
- PubMed, Journal of Women's Health 2022, RECONNECT subgroup analyses (PMID 35230162): Prespecified subgroup analyses of RECONNECT examined effects by age and menopausal proximity
- PubMed, Drug and Therapeutics Bulletin 2021 (PMID 34642243): Paper argues bremelanotide and flibanserin approvals rested on questionable regulatory precedent comparisons
- PubMed, The Medical Letter 2019, Bremelanotide (Vyleesi) (PMID 31381550): Approved dosing is 1.75 mg subcutaneous at least 45 minutes before activity, max once daily and 8 times monthly, with documented blood pressure and nausea effects
- PubMed, CNS Spectrums 2022, neurobiology of bremelanotide (PMID 33455598): Bremelanotide acts on central melanocortin pathways in hypothalamic circuits tied to sexual motivation, distinct from vascular drugs
- PubMed, Journal of Sexual Medicine 2019, Phase 2b responder analyses (PMID 31277966): Phase 2b dose-ranging study responder analyses informed selection of the 1.75 mg approved dose
- PubMed, Journal of Sex Research 2024, Small Effects Questionable Outcomes (PMID 36809187): Paper argues bremelanotide's clinical benefit magnitude is small relative to its side effect burden
- PubMed, Medicina 2022, Management of Hypertension with Female Sexual Dysfunction (PMID 35630054): Review addresses managing hypertension in the context of female sexual dysfunction treatment including bremelanotide
- PubMed, Journal of Sex Research 2021, Re-Analyzing Phase III Bremelanotide Trials (PMID 33678061): Re-analysis of phase 3 trials raised concerns about how HSDD outcomes were measured and interpreted
- PubMed, Diabetes Obesity and Metabolism 2022 (PMID 35170192): Two phase 1 randomized controlled trials examined bremelanotide's effect on body weight in obese women